Provided herein is a method of reducing postprandial concentrations of glucose in a subject's blood comprising administering to the subject, prior to or during a meal, an effective amount of a combination of a marine peptide and a fish nucleotide, sufficient to reduce the glucose concentration in the subject's blood. Further provided herein is a method of reducing postprandial concentration of ghrelin in a subject's blood, comprising administering to the subject, prior to or during a meal, an effective amount of a combination of a marine peptide and a fish nucleotide sufficient to increase the blood component wherein the combination is administered to the subject.

Provided herein is a method of reducing postprandial concentrations of glucose in a subject's blood comprising administering to the subject, prior to or during a meal, an effective amount of a combination of a marine peptide and a fish nucleotide, sufficient to reduce the glucose concentration in the subject's blood. Further provided herein is a method of reducing postprandial concentration of ghrelin in a subject's blood, comprising administering to the subject, prior to or during a meal, an effective amount of a combination of a marine peptide and a fish nucleotide sufficient to increase the blood component wherein the combination is administered to the subject.

Protein formulations with high protein content are disclosed. Also disclosed are methods of using the provided protein formulations.

Protein formulations with high protein content are disclosed. Also disclosed are methods of using the provided protein formulations.

Methods of making mixed allergen drug products are provided, wherein the mixed allergen drug products are of known potency and identity and substantially free of replication viable organisms.

Methods of making mixed allergen drug products are provided, wherein the mixed allergen drug products are of known potency and identity and substantially free of replication viable organisms.

A protein hydrolysate obtained from at least one protein source from bluefish having (i) a degree of hydrolysis (DH) of at least 10%, (ii) at least 80% water-soluble protein with a molecular weight of less than 1000 Da, (iii) at least 0.3% phospholipids, and (iv) at least 0.5% DHA and EPA.

A protein hydrolysate obtained from at least one protein source from bluefish having (i) a degree of hydrolysis (DH) of at least 10%, (ii) at least 80% water-soluble protein with a molecular weight of less than 1000 Da, (iii) at least 0.3% phospholipids, and (iv) at least 0.5% DHA and EPA.

Compositions containing apoaequorin and vitamin D and methods for their use in treating symptoms and disorders related to calcium imbalances and vitamin D deficiency associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.

Compositions containing apoaequorin and vitamin D and methods for their use in treating symptoms and disorders related to calcium imbalances and vitamin D deficiency associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.